Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAF237 50 mg twice daily versus once daily in drug-naive type 2 diabetes
2004-002466-38Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vildagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novartis. Primary endpoint: Change from baseline in HbA1c at Week 12. Started Sep 2004; status: completed.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2004-002466-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002466-38.